Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Summit Therapeutics Inc. - Common Stock
(NQ:
SMMT
)
14.98
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst
↗
July 23, 2026
Via
Chartmill
Summit Therapeutics Q2 Earnings Call Highlights
↗
July 23, 2026
Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail...
Via
MarketBeat
Topics
Earnings
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026
From
Summit Therapeutics
Via
Business Wire
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics (NASDAQ:SMMT) Reports Widening Q4 Losses Amid Aggressive Clinical Push
↗
February 23, 2026
Via
Chartmill
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026
From
Summit Therapeutics
Via
Business Wire
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
June 30, 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Via
The Motley Fool
Topics
Artificial Intelligence
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 09, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
June 04, 2026
From
Summit Therapeutics
Via
Business Wire
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
↗
May 31, 2026
Biotech companies have always licensed programs, but never so many from one region in particular.
Via
The Motley Fool
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
May 31, 2026
From
Summit Therapeutics
Via
Business Wire
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
May 30, 2026
From
Summit Therapeutics
Via
Business Wire
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
↗
May 23, 2026
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
↗
May 23, 2026
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
Via
The Motley Fool
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 2026
From
USA News Group
Via
GlobeNewswire
What's going on in today's session
↗
May 01, 2026
Via
Chartmill
Which stocks are moving on Friday?
↗
May 01, 2026
Via
Chartmill
Summit Therapeutics Stock Dips After Q1 Financial Report
↗
May 01, 2026
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
May 01, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
May 01, 2026
Via
Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
April 30, 2026
Via
Chartmill
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
April 30, 2026
From
Summit Therapeutics
Via
Business Wire
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
March 27, 2026
From
Summit Therapeutics
Via
Business Wire
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
↗
March 25, 2026
The next 10 months might be challenging for this biotech.
Via
The Motley Fool
Summit Therapeutics to Present at Upcoming Investor Conferences
February 26, 2026
From
Summit Therapeutics
Via
Business Wire
Summit (SMMT) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
Summit (SMMT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
February 23, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
February 17, 2026
From
Summit Therapeutics
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
